[go: up one dir, main page]

US7462634B2 - N-(pyridin-2-yl)-sulfonamide derivatives - Google Patents

N-(pyridin-2-yl)-sulfonamide derivatives Download PDF

Info

Publication number
US7462634B2
US7462634B2 US11/455,065 US45506506A US7462634B2 US 7462634 B2 US7462634 B2 US 7462634B2 US 45506506 A US45506506 A US 45506506A US 7462634 B2 US7462634 B2 US 7462634B2
Authority
US
United States
Prior art keywords
compounds
refers
unless
term
indicated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US11/455,065
Other languages
English (en)
Other versions
US20070072914A1 (en
Inventor
Sajiv Krishnan Nair
Michael Siu
Wendy Dianne Taylor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agouron Pharmaceuticals LLC
Pfizer Inc
Original Assignee
Agouron Pharmaceuticals LLC
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agouron Pharmaceuticals LLC, Pfizer Inc filed Critical Agouron Pharmaceuticals LLC
Priority to US11/455,065 priority Critical patent/US7462634B2/en
Publication of US20070072914A1 publication Critical patent/US20070072914A1/en
Application granted granted Critical
Publication of US7462634B2 publication Critical patent/US7462634B2/en
Expired - Fee Related legal-status Critical Current
Adjusted expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/76—Nitrogen atoms to which a second hetero atom is attached
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

  • the present invention relates to novel compounds, to pharmaceutical compositions comprising the compounds, as well as to the use of the compounds in medicine and for the preparation of a medicament which acts on the human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme (11 ⁇ HSD1).
  • 11 ⁇ HSD1 human 11- ⁇ -hydroxysteroid dehydrogenase type 1 enzyme
  • glucocorticoids have a central role in diabetes. For example, the removal of the pituitary or the adrenal gland from a diabetic animal alleviates the most severe symptoms of diabetes and lowers the concentration of glucose in the blood (Long, C. D. and F. D. W. Leukins (1936) J. Exp. Med. 63: 465-490; Houssay, B. A. (1942) Endocrinology 30: 884-892). Additionally, it is also well established that glucocorticoids enable the effect of glucagon on the liver.
  • 11 ⁇ HSD1 as an important regulator of local glucocorticoid effects and thus of hepatic glucose production is well substantiated (see e.g. Jamieson et al. (2000) J. Endocrinol. 165: p. 685-692).
  • the hepatic insulin sensitivity was improved in healthy human volunteers treated with the non-specific 11 ⁇ HSD1 inhibitor carbenoxolone (Walker, B. R., et al. (1995) J. Clin. Endocrinol. Metab. 80: 3155-3159). Furthermore, the expected mechanism has been established by different experiments with mice and rats.
  • Metabolic Syndrome e.g. raised blood pressure, decreased levels of HDL and increased levels of VLDL
  • omental fat appears to be of central importance.
  • Inhibition of the enzyme in pre-adipocytes (stromal cells) has been shown to decrease the rate of differentiation into adipocytes. This is predicted to result in diminished expansion (possibly reduction) of the omental fat depot, i.e. reduced central obesity (Bujalska, I. J., Kumar, S., and Stewart, P. M. (1997) Lancet 349: 1210-1213).
  • the compounds of the present invention are useful as 11 ⁇ HSD1 inhibitors.
  • the present invention provides compounds of formula (I) :
  • the invention is directed to said compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 1 is H. In a further embodiment, the invention is directed to said compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 3 is H or CH 3 . In a still further embodiment, the invention is directed to said compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein R 2 is —CH 2 CH 3 .
  • the invention is directed to said compounds of formula (I) or a pharmaceutically acceptable salt thereof, which are chiral.
  • the (+) enantiomer is directed to said compounds of formula (I) or a pharmaceutically acceptable salt thereof, which are chiral.
  • the (+) enantiomer is preferred.
  • the invention provides compounds of formula I, selected from the group:
  • the invention is directed to said compounds of formula (Ib), (Ic), (Id), or a pharmaceutically acceptable salt thereof, wherein each of which is the (+) enantiomer.
  • the invention provides a compound having the formula II
  • the invention provides a pharmaceutical composition
  • a pharmaceutical composition comprising an effective amount of any of the above compounds of formulae I or II, or the pharmaceutically acceptable salts thereof, and a pharmaceutically acceptable carrier.
  • the invention provides a method for treating a disease, condition or disorder which would benefit by treatment with a 11 ⁇ HSD1 inhibitor (such as type 2 diabetes) comprising administering to a mammal an effective amount of any of the above compounds of formula I or II, or the pharmaceutically acceptable salts thereof.
  • a 11 ⁇ HSD1 inhibitor such as type 2 diabetes
  • the invention provides methods for treating metabolic syndrome, insulin resistance syndrome, obesity, glaucoma, hyperlipidemia, hyperglycemia, hyperinsulinemia, osteoporosis, atherosclerosis, dementia, depression, or diseases in which the liver is a target organ, wherein the method comprises administering to a mammal an effective amount of any of the above compounds of formulae I or II, or the pharmaceutically acceptable salts thereof.
  • the invention provides methods for treating glaucoma comprising administering to a mammal an effective amount of any of the above compounds of formulae I or II, or the pharmaceutically acceptable salts thereof, in combination with a prostanoid receptor agonist, wherein said agonist is latanoprost, bimatoprost, travaprost, or unoprost.
  • the invention provides for a compound of formula I or II, or a pharmaceutically acceptable salt thereof, for use as a medicament.
  • the invention provides for the use of a compound of formula I or II, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of a disease, condition or disorder which would benefit by treatment with a 11 ⁇ HSD1 inhibitor (such as type 2 diabetes).
  • a 11 ⁇ HSD1 inhibitor such as type 2 diabetes
  • alkyl refers to saturated monovalent hydrocarbon radicals having straight or branched moieties.
  • alkenyl refers to alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above and including E and Z isomers of said alkenyl moiety.
  • alkynyl refers to alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above.
  • alkoxy refers to O-alkyl groups wherein alkyl is as defined above.
  • amino refers to the —NH 2 radical and any substitutions of the N atom.
  • halogen and “halo,” unless otherwise indicated, refers to fluorine, chlorine, bromine and/or iodine.
  • trifluoromethyl refers to a —CF 3 group.
  • trifluoromethoxy refers to a —OCF 3 group.
  • cyano refers to a —CN group.
  • Ms methanesulfonate
  • Me refers to methyl
  • MeOH unless otherwise indicated, refers to methanol.
  • Et 2 O refers to diethylether
  • EtOH ethanol
  • Et 3 N refers to triethylamine
  • TAA triethylamine
  • EtOAc ethyl acetate
  • AlMe 2 Cl refers to dimethyl aluminum chloride.
  • TFA trifluoroacetic acid
  • HATU N, N,N′,N′-tetramethyluronium hexafluorophosphate
  • THF tetrahydrofuran
  • TIOH thallium(I) hydroxide
  • TIOEt refers to thallium(I) ethoxide.
  • PCy 3 refers to tricyclohexylphosphine.
  • Pd 2 (dba) 3 refers to tris(dibenzylideneacetone)dipalladium(0).
  • Pd(OAc) 2 refers to palladium(II) acetate.
  • Pd(PPh 3 ) 2 Cl 2 refers to dichlorobis(triphenylphosphine)palladium(II).
  • Pd(PPh 3 ) 4 refers to tetrakis(triphenylphophine)palladium(0).
  • Pd(dppf)Cl 2 refers to (1,1′-bis(diphenylphosphino)-ferrocene)dichloropalladium(II), complex with dichloromethane (1:1).
  • G6P glucose-6-phosphate
  • NIDDM non insulin dependent diabetes mellitus
  • NADPH nicotinamide adenine dinucleotide phosphate reduced form
  • CD 3 OD refers to deuteromethanol
  • CD 3 CN refers to deuteroacetonitrile
  • DEAD refers to diethyl azodicarboxylate.
  • TsCH 2 NC refers to tosylmethyl isocyanide
  • DMSO-d 6 or DMSO-D 6 refers to deuterodimethyl sulfoxide.
  • DME 1,2-dimethoxyethane
  • DMF N,N-dimethylformamide
  • DMSO dimethylsulfoxide
  • DIPEA diisopropylethylamine
  • DI deionized
  • KAc potassium acetate
  • mmol refers to millimole
  • mL milliliter
  • mm refers to millimeter
  • g refers to gram
  • min refers to minute
  • ⁇ L refers to microliter
  • ⁇ M refers to micromolar
  • ⁇ m refers to micrometer
  • M refers to molar
  • N refers to normal
  • nm As used herein, the term “nm,” unless otherwise indicated, refers to nanometer.
  • nM As used herein, the term “nM,” unless otherwise indicated, refers to nanoMolar.
  • m/z refers to mass/charge ratio
  • wt/wt refers to weight/weight
  • v/v refers to volume/volume
  • mL/min refers to milliliter/minute.
  • UV ultraviolet
  • API-MS atmospheric pressure chemical ionization mass spectroscopy
  • HPLC high performance liquid chromatograph
  • LC liquid chromatograph
  • LCMS liquid chromatography mass spectroscopy
  • SFC supercritical fluid chromatography
  • aq refers to aqueous
  • ELSD evaporative light scattering detection
  • MS mass spectroscopy
  • HRMS electrospray ionization
  • Analytic As used herein, the term “Anal.,” unless otherwise indicated, refers to analytical.
  • NT refers to not tested.
  • NA refers to not tested.
  • RT room temperature
  • Celite® refers to a white solid diatomite filter agent commercially available from World Minerals located in Los Angeles, Calif. USA.
  • K i refers to values of enzyme inhibition constant.
  • K i app refers to the apparent K i .
  • IC 50 refers to concentrations required for at least 50% enzyme inhibition.
  • substituted refers to that the specified group or moiety bears one or more substituents.
  • unsubstituted means that the specified group bears no substituents.
  • the term “optionally substituted,” unless otherwise indicated, refers to that the specified group is unsubstituted or substituted by one or more substituents.
  • cycloalkyl refers to a non-aromatic, saturated or partially saturated, monocyclic or fused, spiro or unfused bicyclic or tricyclic hydrocarbon referred to herein containing a total of from 3 to 10 carbon atoms, suitably 5-8 ring carbon atoms.
  • exemplary cycloalkyls include rings having from 3-10 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and adamantyl.
  • aryl or “(C 6 -C 10 )aryl,” unless otherwise indicated, refers to an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.
  • heteroaryl or (5-10)-membered heteroaryl,” unless otherwise indicated, refers to aromatic groups containing one to four heteroatoms each selected from O, S and N, wherein each heteroaryl group has from 5-10 atoms, respectively, in its ring system, and with the proviso that the ring of said group does not contain two adjacent O or S atoms.
  • the heteroaryl groups include benzo-fused ring systems.
  • An example of a 5 membered heterocyclic group is thiazolyl
  • an example of a 7 membered ring is azepinyl
  • an example of a 10 membered heterocyclic group is quinolinyl.
  • heteroaryl groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinox
  • oxo refers to ⁇ O.
  • the compounds of the invention are intended to include solvates, hydrates and pharmaceutically acceptable salts of the compounds of formulae I and II and their specific embodiments.
  • solvate is intended to mean a pharmaceutically acceptable solvate form of a specified compound that retains the biological effectiveness of such compound.
  • examples of solvates include compounds of the invention in combination with water, isopropanol, ethanol, methanol, DMSO (dimethylsulfoxide), ethyl acetate, acetic acid, or ethanolamine.
  • the phrase “pharmaceutically acceptable salt(s),” unless otherwise indicated, includes salts of acidic or basic groups which may be present in the claimed compounds.
  • the claimed compounds that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. Further description of the salts of the invention are described below.
  • the term “diseases in which the liver is a target organ,” unless otherwise indicated means diabetes, hepatitis, liver cancer, liver fibrosis, and malaria.
  • the term “metabolic syndrome”, as used herein, unless otherwise indicated means psoriasis, diabetes mellitus, wound healing, inflammation, neurodegenerative diseases, galactosemia, maple syrup urine disease, phenylketonuria, hypersarcosinemia, thymine uraciluria, sulfinuria, isovaleric acidemia, saccharopinuria, 4-hydroxybutyric aciduria, glucose-6-phosphate dehydrogenase deficiency, and pyruvate dehydrogenase deficiency.
  • treating refers to reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • treatment refers to the act of treating as “treating” is defined immediately above.
  • the term “modulate” or “modulating,” refers to the ability of a modulator for a member of the steroid/thyroid superfamily to either directly (by binding to the receptor as a ligand) or indirectly (as a precursor for a ligand or an inducer which promotes production of ligand from a precursor) induce expression of gene(s) maintained under hormone expression control, or to repress expression of gene(s) maintained under such control.
  • ophthalmic diseases refers to diseases of the eye including but not limited to glaucoma, age related macular degeneration (AMD) including exudative (wet AMD) and non-exudative (dry AMD), choroidal neovascularization, retinopathies such as diabetic retinopathy, retinitis pigmentosa and retinopathy of prematurity, diabetic macular edema, retinitis, uveitis, cystoid macular edema and other diseases or conditions of the eye.
  • AMD age related macular degeneration
  • dry AMD non-exudative
  • choroidal neovascularization choroidal neovascularization
  • retinopathies such as diabetic retinopathy, retinitis pigmentosa and retinopathy of prematurity
  • diabetic macular edema diabetic macular edema
  • retinitis retinitis
  • uveitis cystoid ma
  • the term “obesity” or “obese,” refers generally to individuals who are at least about 20-30% over the average weight for his/her age, sex and height.
  • “obese” is defined, for males, as individuals whose body mass index is greater than 27.8 kg/ m 2 , and for females, as individuals whose body mass index is greater than 27.3 kg/m 2 .
  • the invention method is not limited to those who fall within the above criteria. Indeed, the method of the invention can also be advantageously practiced by individuals who fall outside of these traditional criteria, for example, by those who may be prone to obesity.
  • inflammatory disorders refers to disorders such as rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, chondrocalcinosis, gout, inflammatory bowel disease, ulcerative colitis, Crohn's disease, fibromyalgia, and cachexia.
  • the phrase “therapeutically effective amount,” unless otherwise indicated, refers to that amount of drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal, or human that is being sought by a researcher, veterinarian, medical doctor or other.
  • the phrase “amount . . . effective to lower blood glucose levels,” unless otherwise indicated, refers to levels of compound sufficient to provide circulating concentrations high enough to accomplish the desired effect. Such a concentration typically falls in the range of about 10 nM up to 2 ⁇ M; with concentrations in the range of about 100 nM up to 500 nM being preferred. As noted previously, since the activity of different compounds as set forth above may vary considerably, and since individual subjects may present a wide variation in severity of symptoms, it is up to the practitioner to determine a subject's response to treatment and vary the dosages accordingly.
  • insulin resistance refers to the reduced sensitivity to the actions of insulin in the whole body or individual tissues, such as skeletal muscle tissue, myocardial tissue, fat tissue or liver tissue. Insulin resistance occurs in many individuals with or without diabetes mellitus.
  • insulin resistance syndrome refers to the cluster of manifestations that include insulin resistance, hyperinsulinemia, NIDDM, arterial hypertension, central (visceral) obesity, and dyslipidemia.
  • (+) enantiomer refers to the conventions used for naming chiral compounds, based on the compounds' ability to rotate polarized light.
  • Certain functional groups contained within the compounds of the present invention can be substituted for bioisosteric groups, that is, groups that have similar spatial or electronic requirements to the parent group, but exhibit differing or improved physicochemical or other properties. Suitable examples are well known to those of skill in the art, and include, but are not limited to moieties described in Patini et al., Chem. Rev, 1996, 96, 3147-3176 and references cited therein.
  • Isotopically labeled compounds of this invention can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples below, by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.
  • the compound of formula A may be prepared by reacting a compound of formula B with an Ar-sulfonyl halide, Ar-sulfinyl halide, or Ar-sulfinate in the presence of a suitable base such as an amine in a suitable solvent.
  • a suitable base such as an amine in a suitable solvent.
  • Suitable bases include pyridine, triethylamine, and diisopropylethylamine.
  • Suitable solvents include pyridine, dichloromethane, or THF.
  • the aforementioned reaction can be conducted at about room temperature (about 20° C.) or heated for an appropriate time period, such as 2 hours to 16 hours, depending on the solvent system used. After the reaction is substantially completed, the base may be removed in vacuo and the resulting residue may be purified using conventional purification techniques.
  • any of the above compounds of formula I can be converted into other analogous compound by standard chemical manipulations. All starting materials, reagents, and solvents are commercially available and are known to those of skill in the art unless otherwise stated. These chemical manipulations are known to those skilled in the art and include (a) removal of a protecting group by methods outlined in T. W. Greene and P.G.M.
  • the compounds of the present invention may have asymmetric carbon atoms.
  • Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to those skilled in the art, for example, by chromatography or fractional crystallization.
  • Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. Unless otherwise excluded, all such isomers, including diastereomeric mixtures and pure enantiomers are considered as part of the invention.
  • the compounds of the invention that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compounds of the invention from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt.
  • the acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained.
  • the desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.
  • Those compounds that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations.
  • such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques.
  • the chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of the invention.
  • Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium, and magnesium, etc.
  • salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.
  • they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before.
  • stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.
  • the compounds of the present invention may be modulators of 11 ⁇ HSD1.
  • the compounds of the present invention may modulate processes mediated by 11 ⁇ HSD1, which refer to biological, physiological, endocrinological, and other bodily processes which are mediated by receptor or receptor combinations which are responsive to the 11 ⁇ HSD1 inhibitors described herein (e.g., diabetes, hyperlipidemia, obesity, impaired glucose tolerance, hypertension, fatty liver, diabetic complications (e.g. retinopathy, nephropathy, neurosis, cataracts and coronary artery diseases and the like), arteriosclerosis, pregnancy diabetes, polycystic ovary syndrome, cardiovascular diseases (e.g.
  • ischemic heart disease and the like cell injury (e.g.) brain injury induced by strokes and the like) induced by atherosclerosis or ischemic heart disease, gout, inflammatory diseases (e.g. arthrosteitis, pain, pyrexia, rheumatoid arthritis, inflammatory enteritis, acne, sunburn, psoriasis, eczema, allergosis, asthma, GI ulcer, cachexia, autoimmune diseases, pancreatitis and the like), cancer, osteoporosis and cataracts. Modulation of such processes can be accomplished in vitro or in vivo. In vivo modulation can be carried out in a wide range of subjects, such as, for example, humans, rodents, sheep, pigs, cows, and the like.
  • inflammatory diseases e.g. arthrosteitis, pain, pyrexia, rheumatoid arthritis, inflammatory enteritis, acne, sunburn, psoriasis, e
  • the compounds according to the present invention may be used in several indications which involve modulations of 11 ⁇ HSD1 enzyme.
  • the compounds according to the present invention may be used against dementia (See WO97/07789), osteoporosis (See Canalis E 1996, “Mechanisms of Glucocorticoid Action in Bone: Implications to Glucocorticoid-Induced Osteoporosis”, Journal of Clinical Endocrinology and Metabolism, 81, 3441-3447) and may also be used disorders in the immune system (see Franchimont, et.
  • 11 ⁇ HSD1 In the eye, expression of 11 ⁇ HSD1 is confined to basal cells of the corneal epithelium and the non-pigmented epithelialium of the cornea (the site of aqueous production), to ciliary muscle and to the sphincter and dilator muscles of the iris.
  • the distant isoenzyme 11 beta-hydroxysteroid dehydrogenase type 2 is highly expressed in the non-pigmented ciliary epithelium and corneal endothelium. None of the enzymes is found at the trabecular meshwork, the site of drainage.
  • 11 ⁇ HSD1 is suggested to have a role in aqueous production, rather than drainage, but it is presently unknown if this is by interfering with activation of the glucocorticoid or the mineralocorticoid receptor, or both.
  • the compounds of the present invention may also be useful in the treatment of other metabolic disorders associated with impaired glucose utilization and insulin resistance include major late-stage complications of NIDDM, such as diabetic angiopathy, atherosclerosis, diabetic nephropathy, diabetic neuropathy, and diabetic ocular complications such as retinopathy, cataract formation and glaucoma, and many other conditions linked to NIDDM, including dyslipidemia glucocorticoid induced insulin resistance, dyslipidemia, polycysitic ovarian syndrome, obesity, hyperglycemia, hyperlipidemia, hypercholesteremia, hypertriglyceridemia, hyperinsulinemia, and hypertension. Brief definitions of these conditions are available in any medical dictionary, for instance, Stedman's Medical Dictionary (10 th Ed.).
  • the 11 ⁇ HSD1 assay was performed in a 100 mM Triethanolamine buffer pH 8.0, containing 200 mM NaCl, 0.02% n-dodecyl ⁇ -D-maltoside, 5% glycerol, 5 mM ⁇ -mercaptoethanol.
  • a typical reaction for the determination of K iapp values was carried at room temperature in a Corning® u-bottom 96-well plate and is described as follows: 11 ⁇ HSD1 enzyme (5 nM, final concentration) was pre-incubated in the presence of the inhibitor and NADPH (500 ⁇ M, final concentration) for at least 30 minutes in the assay buffer.
  • the reaction was initiated by adding the regenerating system (2 mM Glucose-6-Phosphate, 1 U/mL Glucose-6-Phosphate dehydrogenase, and 6 mM MgCl 2 , all the concentration reported are final in the assay buffer), and 3H-cortisone (200 nM, final concentration). After 60 minutes, 60 ⁇ L of the assay mixture was transferred to a second 96-well plate and mixed with an equal volume of dimethylsulfoxide to stop the reaction.
  • the regenerating system 2 mM Glucose-6-Phosphate, 1 U/mL Glucose-6-Phosphate dehydrogenase, and 6 mM MgCl 2 , all the concentration reported are final in the assay buffer
  • 3H-cortisone 200 nM, final concentration
  • a 15 ⁇ L aliquot from the reaction mixture was loaded into a C-18 column (Polaris C18-A, 50 ⁇ 4.6 mm, 5 ⁇ , 180 Angstrom from Varian) connected to an automated High-throughput Liquid Chromatography instrument developed by Cohesive Technologies, commercially available from Franklin, Mass. USA, with a ⁇ -RAM model 3 Radio-HPLC detector from IN/US, commercially available from Tampa, Fla. USA.
  • the substrate and product peaks were separated by using an isocratic mixture of 43:57 methanol to water (v/v) at a flow rate of 1.0 mL/min.
  • the initial reaction velocities were measured by stopping the reaction at 60 min and by measuring the area of product formation in the absence and the presence of various concentrations of inhibitors.
  • the K iapp values were determined using the equation for tight-binding inhibitor developed by Morrison, J F. (Morrison J F. Biochim Biophys Acta. 1969; 185: 269-86):
  • v i , and v o are the rates of cortisol formation in the presence and in the absence of inhibitor, respectively, I is the inhibitor concentration and E is the 11 ⁇ HSD1 concentration in the assay buffer. All the concentrations reported are the final concentrations in the assay buffer
  • the K iapp values of the compounds of the present invention for the 11 ⁇ HSD1 enzyme may lie typically between about 10 nM and about 10 ⁇ M.
  • the compounds of the present invention that were tested all have K iapp 's in at least one of the above SPA assays of less than 1 ⁇ M, preferably less than 100 nM.
  • Certain preferred groups of compounds possess differential selectivity toward the various 11- ⁇ -HSD's.
  • One group of preferred compounds possesses selective activity towards 11 ⁇ HSD1 over 11 ⁇ -HSD-2.
  • Another preferred group of compounds possesses selective activity towards 11 ⁇ HSD-2 over 11 ⁇ HSD1. (Morrison J F. Biochim Biophys Acta. 1969; 185: 269-86).
  • Percentage of inhibition was determined in a 100 mM Triethanolamine buffer, pH 8.0, 200 mM NaCl, 0.02% n-dodecyl ⁇ -D-maltoside and 5mM ⁇ -ME.
  • a typical reaction was carried on a Corning® u-bottom 96-well plate and is described as follows: 11 ⁇ HSD1 enzyme (5 nM, final concentration) was pre-incubated in the presence of the inhibitor and NADPH (500 ⁇ M, final concentration) for at least 30 minutes in the assay buffer.
  • the reaction was initiated by adding the regenerating system (2 mM Glucose-6-Phosphate, 1 U/mL Glucose-6-Phosphate dehydrogenase, and 6 mM MgCl 2 , all the concentration reported are final in the assay buffer), and 3H-cortisone (200 nM, final concentration). After 60 minutes, 60 ⁇ L of the assay mixture was transferred to a second 96-well plate and mixed with an equal volume of dimethylsulfoxide to stop the reaction.
  • the regenerating system 2 mM Glucose-6-Phosphate, 1 U/mL Glucose-6-Phosphate dehydrogenase, and 6 mM MgCl 2 , all the concentration reported are final in the assay buffer
  • 3H-cortisone 200 nM, final concentration
  • a 15 ⁇ L aliquot from the reaction mixture was loaded into a C-18 column (Polaris C18-A, 50 ⁇ 4.6 mm, 5 ⁇ , 180 Angstrom from Varian) connected to an automated High-throughput Liquid Chromatography instrument developed by Cohesive Technologies commercially available from Franklin, Mass., with a ⁇ -RAM model 3 Radio-HPLC detector from IN/US commercially available from Tampa, Fla.
  • the substrate and product peaks were separated by using an isocratic mixture of 43:57 methanol to water (v/v) at a flow rate of 1.0 mL/min.
  • Percent Inhibition was calculated based on the following equation: (100 ⁇ (3H-Cortisol peak area with inhibitor/3Hcortisol peak area without inhibitor) ⁇ 100). Certain groups of compounds possess differential selectivity toward the various 11- ⁇ -HSD enzymes. One group of compounds possesses selective activity towards 11 ⁇ HSD1 enzyme over 11 ⁇ HSD1-2 enzyme. While another group of compounds possesses selective activity towards 11 ⁇ HSD-2 enzymes over 11 ⁇ HSD1 enzymes.
  • [1,2-3H]-cortisone is commercially available from American Radiolabeled Chemicals Inc. of St. Louis, Mo. USA. NADPH while Glucose-6-Phosphate and Glucose-6-Phosphate dehydrogenase was purchased from Sigma®.
  • Inhibition of 11 ⁇ HSD1 enzyme activity was also measured using human kidney HEK293 stable transfected cells, over-expressing human 11 ⁇ HSD1, and a reporter plasmid containing DNA sequences for specific recognition of glucocorticoid-activated glucocorticoid receptors (GRE), using a method similar to that described in Bujalska et al, Human 11 ⁇ -hydroxysteroid dehydrogenase: Studies on the stably transfected isoforms and localization of the type 2 isozyme within renal tissue, Steroids, 62(1), 1991, 77-82 . These sequences were fused to a luciferase reporter gene (Luc) allowing for quantification of 11 ⁇ HSD1 enzyme modulation.
  • GRE glucocorticoid-activated glucocorticoid receptors
  • 11 ⁇ HSD1 is responsible for converting inactive into active glucocorticoids (cortisone to cortisol, in humans). Cortisol (but not cortisone) binds and activates glucocorticoid receptors (GR), which will result in activation of luciferase and production of light (assay readout). A compound with the capability of inhibiting 11 ⁇ HSD1 will reduce the luciferase signal, as compared to the cortisone control (enzyme substrate).
  • Fa2N4 is a cell line derived from human hepatocytes, developed by MultiCell Technologies, Inc. (U.S. Pat. No. 6,107,043), and commercialized by XenoTech LLC via an exclusive license. These cells are uniquely similar, both morphologically and functionally, to primary cultures, therefore exhibiting many of the characteristics of normal human hepatocytes, and thus providing a virtually limitless and reproducible supply of cells to support drug discovery. Inhibition of 11 ⁇ HSD1 enzyme activity was assessed in this cell model by measuring decrease in cortisol (enzyme product) accumulation in cultures co-treated with cortisone (enzyme substrate) and the potential enzyme inhibitor. Cortisol signal was quantitatively determined in the supernatant of treated cells by means of the Correlate-Enzyme Immunoassay (EIA)TMCortisol kit (Assay Designs, Inc.).
  • EIA Correlate-Enzyme Immunoassay
  • compositions of the claimed compounds include the acid addition and base salts thereof.
  • Suitable acid addition salts are formed from acids which form non-toxic salts. Examples include the acetate, adipate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulphate/sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride/chloride, hydrobromide/bromide, hydroiodide/iodide, isethionate, lactate, malate, maleate, malonate, mesylate, methylsulphate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate/hydrogen phosphate/dihydrogen phosphate, pyroglutamate, saccharate, ste
  • Suitable base salts are formed from bases which form non-toxic salts. Examples include the aluminium, arginine, benzathine, calcium, choline, diethylamine, diolamine, glycine, lysine, magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
  • Hemisalts of acids and bases may also be formed, for example, hemisulphate and hemicalcium salts.
  • compositions may be prepared by one or more of three methods:
  • the resulting salt may precipitate out and be collected by filtration or may be recovered by evaporation of the solvent.
  • the degree of ionisation in the resulting salt may vary from completely ionised to almost non-ionised.
  • the compounds of the invention may exist in a continuum of solid states ranging from fully amorphous to fully crystalline.
  • amorphous refers to a state in which the material lacks long range order at the molecular level and, depending upon temperature, may exhibit the physical properties of a solid or a liquid. Typically such materials do not give distinctive X-ray diffraction patterns and, while exhibiting the properties of a solid, are more formally described as a liquid.
  • a change from solid to liquid properties occurs which is characterized by a change of state, typically second order (‘glass transition’).
  • crystalline refers to a solid phase in which the material has a regular ordered internal structure at the molecular level and gives a distinctive X-ray diffraction pattern with defined peaks. Such materials when heated sufficiently will also exhibit the properties of a liquid, but the change from solid to liquid is characterized by a phase change, typically first order (‘melting point’).
  • the compounds of the invention may also exist in unsolvated and solvated forms.
  • solvate is used herein to describe a molecular complex comprising the compound of the invention and one or more pharmaceutically acceptable solvent molecules, for example, ethanol.
  • solvent molecules for example, ethanol.
  • hydrate is employed when said solvent is water.
  • Isolated site hydrates are ones in which the water molecules are isolated from direct contact with each other by intervening organic molecules.
  • channel hydrates the water molecules lie in lattice channels where they are next to other water molecules.
  • metal-ion coordinated hydrates the water molecules are bonded to the metal ion.
  • the complex When the solvent or water is tightly bound, the complex will have a well-defined stoichiometry independent of humidity. When, however, the solvent or water is weakly bound, as in channel solvates and hygroscopic compounds, the water/solvent content will be dependent on humidity and drying conditions. In such cases, non-stoichiometry will be the norm.
  • multi-component complexes other than salts and solvates
  • complexes of this type include clathrates (drug-host inclusion complexes) and co-crystals.
  • the latter are typically defined as crystalline complexes of neutral molecular constituents which are bound together through non-covalent interactions, but could also be a complex of a neutral molecule with a salt.
  • Co-crystals may be prepared by melt crystallisation, by recrystallisation from solvents, or by physically grinding the components together—see Chem Commun, 17, 1889-1896, by O. Almarsson and M. J. Zaworotko (2004).
  • J Pharm Sci, 64 (8),1269-1288 by Haleblian (August 1975).
  • the compounds of the invention may also exist in a mesomorphic state (mesophase or liquid crystal) when subjected to suitable conditions.
  • the mesomorphic state is intermediate between the true crystalline state and the true liquid state (either melt or solution).
  • Mesomorphism arising as the result of a change in temperature is described as ‘thermotropic’ and that resulting from the addition of a second component, such as water or another solvent, is described as ‘lyotropic’.
  • references to the claimed compounds include references to salts, solvates, multi-component complexes and liquid crystals thereof and to solvates, multi-component complexes and liquid crystals of salts thereof.
  • the compounds of the invention include the claimed compounds as hereinbefore defined, including all polymorphs and crystal habits thereof, prodrugs and isomers thereof (including optical, geometric and tautomeric isomers) as hereinafter defined and isotopically-labeled claimed compounds.
  • prodrugs of the claimed compounds are also within the scope of the invention.
  • certain derivatives of the claimed compounds which may have little or no pharmacological activity themselves can, when administered into or onto the body, be converted into the claimed compounds having the desired activity, for example, by hydrolytic cleavage.
  • Such derivatives are referred to as ‘prodrugs’.
  • Further information on the use of prodrugs may be found in Pro-drugs as Novel Delivery Systems , Vol. 14, ACS Symposium Series (T. Higuchi and W. Stella) and Bioreversible Carriers in Drug Design , Pergamon Press, 1987 (Ed. E. B. Roche, American Pharmaceutical Association).
  • Prodrugs in accordance with the invention can, for example, be produced by replacing appropriate functionalities present in the claimed compounds with certain moieties known to those skilled in the art as ‘pro-moieties’ as described, for example, in Design of Prodrugs by H. Bundgaard (Elsevier, 1985).
  • prodrugs in accordance with the invention include
  • the claimed compounds contains a carboxylic acid functionality (—COOH), an ester thereof, for example, a compound wherein the hydrogen of the carboxylic acid functionality of the claimed compounds is replaced by (C 1 -C 8 )alkyl;
  • the claimed compounds contains a primary or secondary amino functionality (—NH 2 or —NHR where R ⁇ H), an amide thereof, for example, a compound wherein, as the case may be, one or both hydrogens of the amino functionality of the claimed compounds is/are replaced by (C 1 -C 10 )alkanoyl.
  • metabolites of compounds of the claimed compounds that is, compounds formed in vivo upon administration of the drug.
  • Some examples of metabolites in accordance with the invention include
  • the claimed compounds containing one or more asymmetric carbon atoms can exist as two or more stereoisomers. Where the claimed compounds contain an alkenyl or alkenylene group, geometric cis/trans (or Z/E) isomers are possible. Where structural isomers are interconvertible via a low energy barrier, tautomeric isomerism (‘tautomerism’) can occur. This can take the form of proton tautomerism in the claimed containing, for example, an imino, keto, or oxime group, or so-called valence tautomerism in compounds which contain an aromatic moiety. It follows that a single compound may exhibit more than one type of isomerism.
  • Cis/trans isomers may be separated by conventional techniques well known to those skilled in the art, for example, chromatography and fractional crystallisation.
  • the racemate (or a racemic precursor) may be reacted with a suitable optically active compound, for example, an alcohol, or, in the case where the claimed compounds contain an acidic or basic moiety, a base or acid such as 1 -phenylethylamine or tartaric acid.
  • a suitable optically active compound for example, an alcohol, or, in the case where the claimed compounds contain an acidic or basic moiety, a base or acid such as 1 -phenylethylamine or tartaric acid.
  • the resulting diastereomeric mixture may be separated by chromatography and/or fractional crystallization and one or both of the diastereoisomers converted to the corresponding pure enantiomer(s) by means well known to a skilled person.
  • Chiral compounds of the invention may be obtained in enantiomerically-enriched form using chromatography, typically HPLC, on an asymmetric resin with a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1% diethylamine. Concentration of the eluate affords the enriched mixture.
  • chromatography typically HPLC
  • a mobile phase consisting of a hydrocarbon, typically heptane or hexane, containing from 0 to 50% by volume of isopropanol, typically from 2% to 20%, and from 0 to 5% by volume of an alkylamine, typically 0.1% diethylamine.
  • the first type is the racemic compound (true racemate) referred to above wherein one homogeneous form of crystal is produced containing both enantiomers in equimolar amounts.
  • the second type is the racemic mixture or conglomerate wherein two forms of crystal are produced in equimolar amounts each comprising a single enantiomer.
  • Racemic mixtures may be separated by conventional techniques known to those skilled in the art—see, for example, Stereochemistry of Organic Compounds by E. L. Eliel and S. H. Wilen (Wiley, 1994).
  • the present invention includes all pharmaceutically acceptable isotopically-labelled claimed compounds wherein one or more atoms are replaced by atoms having the same atomic number, but an atomic mass or mass number different from the atomic mass or mass number which predominates in nature.
  • isotopes suitable for inclusion in the compounds of the invention include isotopes of hydrogen, such as 2 H and 3 H, carbon, such as 11 C, 13 C and 14 C, chlorine, such as 36 Cl, fluorine, such as 18 F, iodine, such as 123 I and 125 I, nitrogen, such as 13 N and 15 N, oxygen, such as 15 O, 17 O and 18 O, phosphorus, such as 32 P, and sulphur, such as 35 S.
  • Radioactive isotopes tritium, i.e. 3 H, and carbon-14, i.e. 14 C, are particularly useful for this purpose in view of their ease of incorporation and ready means of detection.
  • substitution with heavier isotopes such as deuterium, i.e. 2 H, may afford certain therapeutic advantages resulting from greater metabolic stability, for example, increased in vivo half-life or reduced dosage requirements, and hence may be preferred in some circumstances.
  • Isotopically-labeled claimed compounds can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described in the accompanying Examples and Preparations using an appropriate isotopically-labeled reagent in place of the non-labeled reagent previously employed.
  • solvates in accordance with the invention include those wherein the solvent of crystallization may be isotopically substituted, e.g. D 2 O, d 6 -acetone, d 6 -DMSO.
  • intermediate compounds of the claimed compounds as hereinbefore defined all salts, solvates and complexes thereof and all solvates and complexes of salts thereof as defined hereinbefore for compounds of the claimed compounds.
  • the invention includes all polymorphs of the aforementioned species and crystal habits thereof.
  • the claimed compounds should be assessed for their biopharmaceutical properties, such as solubility and solution stability (across pH), permeability, etc., in order to select the most appropriate dosage form and route of administration for treatment of the proposed indication.
  • Compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose.
  • anti-infectives including, without limitation, antibiotics, antivirals, and antifungals; antiallergenic agents and mast cell stabilizers; steroidal and nonsteroidal anti-inflammatory agents (such as nepafenac); cyclooxygenase inhibitors, including, without limitation, Cox I and Cox II inhibitors; combinations of anti-infective and anti-inflammatory agents; decongestants; anti-glaucoma agents, including, without limitation, adrenergics, beta-adrenergic blocking agents, alpha-adrenergic agonists, parasypathomimetic agents, cholinesterase inhibitors, carbonic anhydrase inhibitors, and prostaglandins; combinations of anti-glaucoma agents; antioxidants; nutritional supplements; drugs for the treatment of cystoid macular edema including
  • compositions of the invention will be administered as a formulation in association with one or more pharmaceutically acceptable excipients.
  • excipient is used herein to describe any ingredient other than the compound(s) of the invention.
  • the choice of excipient will to a large extent depend on factors such as the particular mode of administration, the effect of the excipient on solubility and stability, and the nature of the dosage form.
  • compositions suitable for the delivery of compounds of the present invention and methods for their preparation will be readily apparent to those skilled in the art. Such compositions and methods for their preparation may be found, for example, in Remington's Pharmaceutical Sciences, 19th Edition (Mack Publishing Company, 1995).
  • the compounds of the invention may be administered orally.
  • Oral administration may involve swallowing, so that the compound enters the gastrointestinal tract, and/or buccal, lingual, or sublingual administration by which the compound enters the blood stream directly from the mouth.
  • Formulations suitable for oral administration include solid, semi-solid and liquid systems such as tablets; soft or hard capsules containing multi- or nano-particulates, liquids, or powders; lozenges (including liquid-filled); chews; gels; fast dispersing dosage forms; films; ovules; sprays; and buccal/mucoadhesive patches.
  • Liquid formulations include suspensions, solutions, syrups and elixirs. Such formulations may be employed as fillers in soft or hard capsules (made, for example, from gelatin or hydroxypropylmethylcellulose) and typically comprise a carrier, for example, water, ethanol, polyethylene glycol, propylene glycol, methylcellulose, or a suitable oil, and one or more emulsifying agents and/or suspending agents. Liquid formulations may also be prepared by the reconstitution of a solid, for example, from a sachet.
  • the compounds of the invention may also be used in fast-dissolving, fast-disintegrating dosage forms such as those described in Expert Opinion in Therapeutic Patents, 11 (6), 981-986, by Liang and Chen (2001).
  • the drug may make up from 1 weight % to 80 weight % of the dosage form, more typically from 5 weight % to 60 weight % of the dosage form.
  • tablets generally contain a disintegrant.
  • disintegrants include sodium starch glycolate, sodium carboxymethyl cellulose, calcium carboxymethyl cellulose, croscarmellose sodium, crospovidone, polyvinylpyrrolidone, methyl cellulose, microcrystalline cellulose, lower alkyl-substituted hydroxypropyl cellulose, starch, pregelatinised starch and sodium alginate.
  • the disintegrant will comprise from 1 weight % to 25 weight %, preferably from 5 weight % to 20 weight % of the dosage form.
  • Binders are generally used to impart cohesive qualities to a tablet formulation. Suitable binders include microcrystalline cellulose, gelatin, sugars, polyethylene glycol, natural and synthetic gums, polyvinylpyrrolidone, pregelatinised starch, hydroxypropyl cellulose and hydroxypropyl methylcellulose.
  • Tablets may also contain diluents, such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
  • diluents such as lactose (monohydrate, spray-dried monohydrate, anhydrous and the like), mannitol, xylitol, dextrose, sucrose, sorbitol, microcrystalline cellulose, starch and dibasic calcium phosphate dihydrate.
  • Tablets may also optionally comprise surface active agents, such as sodium lauryl sulfate and polysorbate 80, and glidants such as silicon dioxide and talc.
  • surface active agents such as sodium lauryl sulfate and polysorbate 80
  • glidants such as silicon dioxide and talc.
  • surface active agents may comprise from 0.2 weight % to 5 weight % of the tablet, and glidants may comprise from 0.2 weight % to 1 weight % of the tablet.
  • Tablets also generally contain lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate.
  • lubricants such as magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and mixtures of magnesium stearate with sodium lauryl sulphate.
  • Lubricants generally comprise from 0.25 weight % to 10 weight %, preferably from 0.5 weight % to 3 weight % of the tablet.
  • ingredients include anti-oxidants, colourants, flavouring agents, preservatives and taste-masking agents.
  • Exemplary tablets contain up to about 80% drug, from about 10 weight % to about 90 weight % binder, from about 0 weight % to about 85 weight % diluent, from about 2 weight % to about 10 weight % disintegrant, and from about 0.25 weight % to about 10 weight % lubricant.
  • Tablet blends may be compressed directly or by roller to form tablets. Tablet blends or portions of blends may alternatively be wet-, dry-, or melt-granulated, melt congealed, or extruded before tabletting.
  • the final formulation may comprise one or more layers and may be coated or uncoated; it may even be encapsulated.
  • Consumable oral films for human or veterinary use are typically pliable water-soluble or water-swellable thin film dosage forms which may be rapidly dissolving or mucoadhesive and typically comprise the claimed compounds, a film-forming polymer, a binder, a solvent, a humectant, a plasticiser, a stabiliser or emulsifier, a viscosity-modifying agent and a solvent. Some components of the formulation may perform more than one function.
  • the claimed compounds may be water-soluble or insoluble.
  • a water-soluble compound typically comprises from 1 weight % to 80 weight %, more typically from 20 weight % to 50 weight %, of the solutes. Less soluble compounds may comprise a greater proportion of the composition, typically up to 88 weight % of the solutes.
  • the claimed compounds may be in the form of multiparticulate beads.
  • the film-forming polymer may be selected from natural polysaccharides, proteins, or synthetic hydrocolloids and is typically present in the range 0.01 to 99 weight %, more typically in the range 30 to 80 weight %.
  • ingredients include anti-oxidants, colorants, flavourings and flavour enhancers, preservatives, salivary stimulating agents, cooling agents, co-solvents (including oils), emollients, bulking agents, anti-foaming agents, surfactants and taste-masking agents.
  • Films in accordance with the invention are typically prepared by evaporative drying of thin aqueous films coated onto a peelable backing support or paper. This may be done in a drying oven or tunnel, typically a combined coater dryer, or by freeze-drying or vacuuming.
  • Solid formulations for oral administration may be formulated to be immediate and/or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • Suitable modified release formulations for the purposes of the invention are described in U.S. Pat. No. 6,106,864, herein incorporated by reference in its entirety. Details of other suitable release technologies such as high energy dispersions and osmotic and coated particles are to be found in Pharmaceutical Technology On - line, 25(2), 1-14, by Verma et al (2001). The use of chewing gum to achieve controlled release is described in WO 00/35298.
  • the compounds of the invention may also be administered directly into the blood stream, into muscle, or into an internal organ.
  • Suitable means for parenteral administration include intravenous, intraarterial, intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal, intracranial, intramuscular, intrasynovial and subcutaneous.
  • Suitable devices for parenteral administration include needle (including microneedle) injectors, needle-free injectors and infusion techniques.
  • Parenteral formulations are typically aqueous solutions which may contain excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but, for some applications, they may be more suitably formulated as a sterile non-aqueous solution or as a dried form to be used in conjunction with a suitable vehicle such as sterile, pyrogen-free water.
  • excipients such as salts, carbohydrates and buffering agents (preferably to a pH of from 3 to 9)
  • a suitable vehicle such as sterile, pyrogen-free water.
  • parenteral formulations under sterile conditions may readily be accomplished using standard pharmaceutical techniques well known to those skilled in the art.
  • solubility of the claimed compounds used in the preparation of parenteral solutions may be increased by the use of appropriate formulation techniques, such as the incorporation of solubility-enhancing agents.
  • Formulations for parenteral administration may be formulated to be immediate and/or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • compounds of the invention may be formulated as a suspension or as a solid, semi-solid, or thixotropic liquid for administration as an implanted depot providing modified release of the active compound.
  • examples of such formulations include drug-coated stents and semi-solids and suspensions comprising drug-loaded poly(dl-lactic-coglycolic)acid (PGLA) microspheres.
  • PGLA poly(dl-lactic-coglycolic)acid
  • the compounds of the invention may also be administered topically, (intra)dermally, or transdermally to the skin or mucosa.
  • Typical formulations for this purpose include gels, hydrogels, lotions, solutions, creams, ointments, dusting powders, dressings, foams, films, skin patches, wafers, implants, sponges, fibres, bandages and microemulsions. Liposomes may also be used.
  • Typical carriers include alcohol, water, mineral oil, liquid petrolatum, white petrolatum, glycerin, polyethylene glycol and propylene glycol. Penetration enhancers may be incorporated—see, for example, J Pharm Sci, 88 (10), 955-958, by Finnin and Morgan (October 1999).
  • topical administration include delivery by electroporation, iontophoresis, phonophoresis, sonophoresis and microneedle or needle-free (e.g. PowderjectTM, BiojectTM, etc.) injection.
  • Formulations for topical administration may be formulated to be immediate and/or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • the compounds of the invention can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids, such as phosphatidylcholine) from a dry powder inhaler, as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, or as nasal drops.
  • the powder may comprise a bioadhesive agent, for example, chitosan or cyclodextrin.
  • the pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the compound(s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
  • a solution or suspension of the compound(s) of the invention comprising, for example, ethanol, aqueous ethanol, or a suitable alternative agent for dispersing, solubilising, or extending release of the active, a propellant(s) as solvent and an optional surfactant, such as sorbitan trioleate, oleic acid, or an oligolactic acid.
  • the drug product Prior to use in a dry powder or suspension formulation, the drug product is micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
  • comminuting method such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
  • Capsules made, for example, from gelatin or hydroxypropylmethylcellulose
  • blisters and cartridges for use in an inhaler or insulator may be formulated to contain a powder mix of the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as l-leucine, mannitol, or magnesium stearate.
  • the lactose may be anhydrous or in the form of the monohydrate, preferably the latter.
  • Other suitable excipients include dextran, glucose, maltose, sorbitol, xylitol, fructose, sucrose and trehalose.
  • a suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1 ⁇ g to 20 mg of the compound of the invention per actuation and the actuation volume may vary from 1 ⁇ l to 100 ⁇ l.
  • a typical formulation may comprise the claimed compounds, propylene glycol, sterile water, ethanol and sodium chloride.
  • Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.
  • Suitable flavours such as menthol and levomenthol, or sweeteners, such as saccharin or saccharin sodium, may be added to those formulations of the invention intended for inhaled/intranasal administration.
  • Formulations for inhaled/intranasal administration may be formulated to be immediate and/or modified release using, for example, PGLA.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • the compounds of the invention may be administered rectally or vaginally, for example, in the form of a suppository, pessary, or enema.
  • Cocoa butter is a traditional suppository base, but various alternatives may be used as appropriate.
  • Formulations for rectal/vaginal administration may be formulated to be immediate and/or modified release.
  • Modified release formulations include delayed-, sustained-, pulsed-, controlled-, targeted and programmed release.
  • a compound of the present invention is delivered in a pharmaceutically acceptable ophthalmic vehicle such that the compound is maintained in contact with the ocular surface for a sufficient time period to allow the compound to penetrate the cornea and/or sclera and internal regions of the eye, including, for example; the anterior chamber, posterior chamber, vitreous body, aqueous humor, vitreous humor, cornea, iris/cilary, lens, choroid/retina and sclera.
  • the pharmaceutically acceptable ophthalmic vehicle may be an ointment, vegetable oil, or an encapsulating material.
  • a compound of the invention may also be injected directly into the vitreous humor or aqueous humor.
  • a compound may be also be administered by well-known, acceptable methods, such as subtebnon and/or subconjunctival injections.
  • a depot of a specific quantity of an ophthalmically acceptable pharmaceutically active agent directly on the outer surface of the sclera and below Tenon's capsule.
  • the depot directly on the outer surface of the sclera, below Tenon's capsule, and generally above the macula.
  • the compounds may also be formulated as a depot preparation.
  • Such long-acting formulations may be administered by implantation (for example, subcutaneously or intramuscularly) intramuscular injection or by the above mentioned subtenon or intravitreal injection.
  • the compounds may be prepared for topical administration in saline (combined with any of the preservatives and antimicrobial agents commonly used in ocular preparations), and administered in eyedrop form.
  • the solution or suspension may be prepared in its pure form and administered several times daily.
  • present compositions, prepared as described above, may also be administered directly to the cornea.
  • the active ingredient may be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • a suitable vehicle e.g., sterile pyrogen-free water
  • the composition is prepared with a muco-adhesive polymer which binds to cornea.
  • the compounds may be formulated with suitable polymeric or hydrophobic materials (for example, as an emulsion in an acceptable oil) or ion-exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • compositions may be utilized as an adjunct to conventional steroid therapy.
  • a pharmaceutical carrier for hydrophobic compounds is a cosolvent system comprising benzyl alcohol, a nonpolar surfactant, a water-miscible organic polymer, and an aqueous phase.
  • the cosolvent system may be a VPD co-solvent system.
  • VPD is a solution of 3% w/v benzyl alcohol, 8% w/v of the nonpolar surfactant polysorbate 80, and 65% w/v polyethylene glycol 300, made up to volume in absolute ethanol.
  • the VPD co-solvent system (VPD:5W) contains VPD diluted 1:1 with a 5% dextrose in water solution.
  • This co-solvent system dissolves hydrophobic compounds well, and itself produces low toxicity upon systemic administration.
  • the proportions of a co-solvent system may be varied considerably without destroying its solubility and toxicity characteristics.
  • identity of the co-solvent components may be varied: for example, other low-toxicity nonpolar surfactants may be used instead of polysorbate 80; the fraction size of polyethylene glycol may be varied; other biocompatible polymers may replace polyethylene glycol, e.g. polyvinyl pyrrolidone; and other sugars or polysaccharides may be substituted for dextrose.
  • hydrophobic pharmaceutical compounds may be employed.
  • Liposomes and emulsions are known examples of delivery vehicles or carriers for hydrophobic drugs.
  • Certain organic solvents such as dimethylsulfoxide also may be employed, although usually at the cost of greater toxicity.
  • the compounds may be delivered using a sustained-release system, such as semipermeable matrices of solid hydrophobic polymers containing the therapeutic agent.
  • sustained-release materials have been established and are known by those skilled in the art. Sustained-release capsules may, depending on their chemical nature, release the compounds for a few weeks up to over 100 days. Depending on the chemical nature and the biological stability of the therapeutic reagent, additional strategies for protein stabilization may be employed.
  • compositions also may comprise suitable solid- or gel-phase carriers or excipients.
  • suitable solid- or gel-phase carriers or excipients include calcium carbonate, calcium phosphate, sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • the compounds of the invention may be combined with soluble macromolecular entities, such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers, in order to improve their solubility, dissolution rate, taste-masking, bioavailability and/or stability for use in any of the aforementioned modes of administration.
  • soluble macromolecular entities such as cyclodextrin and suitable derivatives thereof or polyethylene glycol-containing polymers
  • Drug-cyclodextrin complexes are found to be generally useful for most dosage forms and administration routes. Both inclusion and non-inclusion complexes may be used.
  • the cyclodextrin may be used as an auxiliary additive, i.e. as a carrier, diluent, or solubiliser. Most commonly used for these purposes are alpha-, beta- and gamma-cyclodextrins, examples of which may be found in International Patent Applications Nos. WO 91/11172, WO 94/02518 and WO 98/55148.
  • compositions may conveniently be combined in the form of a kit suitable for coadministration of the compositions.
  • kit of the invention comprises two or more separate pharmaceutical compositions, at least one of which contains the claimed compounds in accordance with the invention, and means for separately retaining said compositions, such as a container, divided bottle, or divided foil packet.
  • a container, divided bottle, or divided foil packet is an example of such a kit.
  • An example of such a kit is the familiar blister pack used for the packaging of tablets, capsules and the like.
  • the kit of the invention is particularly suitable for administering different dosage forms, for example, oral and parenteral, for administering the separate compositions at different dosage intervals, or for titrating the separate compositions against one another.
  • the kit typically comprises directions for administration and may be provided with a so-called memory aid.
  • the total daily dose of the compounds of the invention is typically in the range 0.5 mg/kg body wieght to about 100 mg/kg depending, of course, on the mode of administration.
  • the preferred dosage rate is between 30 mg/kg body weight to about 100 mg/kg body weight.
  • the total daily dose may be administered in single or divided doses and may, at the physician's discretion, fall outside of the typical range given herein.
  • These dosages are based on an average human subject having a weight of about 60 kg to 70 kg. The physician will readily be able to determine doses for subjects whose weight falls outside this range, such as infants and the elderly.
  • references herein to “treatment” include references to curative, palliative and prophylactic treatment.
  • the resulting residue was diluted with acetic acid (1 mL) and methanol (1 mL) and stirred for 0.5 h.
  • the reaction mixture was then diluted with ethyl acetate (50 mL) and washed with saturated aqueous NaHCO 3 solution (2 ⁇ 30 mL).
  • the organic layer was concentrated, and the resulting residue was purified by flash column chromatography (1:1 hexanes/ethyl acetate).
  • the racemic product was converted to the hydrochloride salt by dissolving in diethyl ether (5 mL) and adding HCl (1 N in Et 2 O) to afford the titled racemic product as a white solid (0.21 g, 37%).
  • the racemic free base was separated by a preparative enantioseparation method which was developed using supercritical fluid chromatography (SFC) technology, with supercritical carbon dioxide providing the bulk of the mobile phase.
  • SFC supercritical fluid chromatography
  • the separation and isolation of chiral enantiomers was carried out on a Berger SFC MultiGramTM Purification System (Mettler Toledo AutoChem, Inc.).
  • the preparative chromatography conditions used to separate the enantiomers consisted of a Chiralpak AD-H (amylose tris-(3,5-dimethylphenylcarbamate)) 250 ⁇ 21 mm, 5 ⁇ semi-preparative column as the chiral stationary phase (Chiral Technologies, Inc.). Column temperature was maintained at 35° C.
  • the mobile phase used was supercritical CO 2 with 40% methanol as the modifier, maintained isocratically at a flow rate of 50 mL/min and a constant pressure of 100 bar.
  • the preparative enantioseparation method was similar to that used for Example 2 above.
  • the preparative chromatography conditions used to separate the enantiomers consisted of a Chiralpak AD-H (amylose tris-(3,5-dimethylphenylcarbamate)) 250 ⁇ 21 mm, 5 ⁇ semi-preparative column as the chiral stationary phase (Chiral Technologies, Inc.). Column temperature was maintained at 35° C.
  • the mobile phase used was supercritical CO 2 with 45% methanol as the modifier, maintained isocratically at a flow rate of 55 mL/min and a constant pressure of 140 bar.
  • the reagent 4-Bromo-2-methyl-N-(6- ⁇ 1-[(trimethylsilyl)oxy]ethyl ⁇ pyridin-2-yl)benzenesulfonamide was made following the procedure described for the preparation of 4′-Cyano-N-[6-(1-hydroxyethyl)pyridin-2-yl]biphenyl-4-sulfonamide in Example 2 above.
  • the preparative enantioseparation method was similar to that used for Example 2 above.
  • the preparative chromatography conditions used to separate the enantiomers consisted of a Chiralcel OJ-H (cellulose tris-(4-methylbenzoate), 250 ⁇ 21 mm, 5 ⁇ semi-preparative column as the chiral stationary phase (Chiral Technologies, Inc.). Column temperature was maintained at 35° C.
  • the mobile phase used was supercritical CO 2 with 25% isopropanol as the modifier, maintained isocratically at a flow rate of 50 mL/min and a constant pressure of 140 bar.
  • the 4-butoxylphenyl sulfonyl chloride 160 ⁇ mol, 2.0 eq, 400 ⁇ L of a 0.40 M in anhydrous pyridine
  • tert-butyl (6-aminopyridin-2-yl)carbamate 80 ⁇ mol, 1.0 eq, 400 ⁇ L of a 0.20 M in anhydrous pyridine
  • the test tube was covered with Parafilm, and was stirred for 24 h at ambient temperature.
  • the solvent (pyridine) was evaporated in vacuo.
  • Trifluoroacetic acid (320 ⁇ L, 52.0 eq., excess, neat) was added into the test tube. The test tube was capped and vortexed for 5 h at ambient temperature. The excess TFA was removed in vacuo, and the residue was dissolved in DMSO (1.340 mL) and purified by HPLC.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
US11/455,065 2005-06-16 2006-06-15 N-(pyridin-2-yl)-sulfonamide derivatives Expired - Fee Related US7462634B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/455,065 US7462634B2 (en) 2005-06-16 2006-06-15 N-(pyridin-2-yl)-sulfonamide derivatives

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US69135005P 2005-06-16 2005-06-16
US74877805P 2005-12-09 2005-12-09
US11/455,065 US7462634B2 (en) 2005-06-16 2006-06-15 N-(pyridin-2-yl)-sulfonamide derivatives

Publications (2)

Publication Number Publication Date
US20070072914A1 US20070072914A1 (en) 2007-03-29
US7462634B2 true US7462634B2 (en) 2008-12-09

Family

ID=36889285

Family Applications (1)

Application Number Title Priority Date Filing Date
US11/455,065 Expired - Fee Related US7462634B2 (en) 2005-06-16 2006-06-15 N-(pyridin-2-yl)-sulfonamide derivatives

Country Status (23)

Country Link
US (1) US7462634B2 (es)
EP (1) EP1893609B1 (es)
JP (1) JP4250675B2 (es)
KR (1) KR20080016649A (es)
AR (1) AR055060A1 (es)
AT (1) ATE449094T1 (es)
AU (1) AU2006257646A1 (es)
BR (1) BRPI0611853A2 (es)
CA (1) CA2610903A1 (es)
DE (1) DE602006010546D1 (es)
EA (1) EA200702498A1 (es)
ES (1) ES2334518T3 (es)
GT (1) GT200600258A (es)
IL (1) IL187695A0 (es)
MA (1) MA29550B1 (es)
MX (1) MX2007016319A (es)
NL (1) NL1031976C2 (es)
NO (1) NO20080164L (es)
PE (1) PE20070136A1 (es)
TN (1) TNSN07476A1 (es)
TW (1) TWI304062B (es)
UY (1) UY29606A1 (es)
WO (1) WO2006134467A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2061767B1 (de) 2006-08-08 2014-12-17 Sanofi Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
GB0705400D0 (en) 2007-03-21 2007-05-02 Univ Aberdeen Therapeutic compounds andm their use
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
US8470841B2 (en) 2008-07-09 2013-06-25 Sanofi Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
US20100022572A1 (en) 2008-07-18 2010-01-28 Kowa Company, Ltd. Novel spiro compound and medicine comprising the same
TW201010975A (en) 2008-08-29 2010-03-16 Kowa Co 1-adamantylazetidin-2-one derivatives and drugs containing same
GB0817208D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd Therapeutic apsap compounds and their use
GB0817207D0 (en) 2008-09-19 2008-10-29 Pimco 2664 Ltd therapeutic apsac compounds and their use
US8252781B2 (en) 2008-10-29 2012-08-28 Kowa Company, Ltd. 1,2-diazetidin-3-one derivatives and drugs containing same
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
US8519178B2 (en) 2009-06-22 2013-08-27 Johnson Matthey Public Limited Company Method for the purification of prostaglandins
CN102482312A (zh) 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
UA112418C2 (uk) 2010-09-07 2016-09-12 Астеллас Фарма Інк. Терапевтичний болезаспокійливий засіб
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120053A1 (de) 2011-03-08 2012-09-13 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
GB201311361D0 (en) 2013-06-26 2013-08-14 Pimco 2664 Ltd Compounds and their therapeutic use
AU2015367528B2 (en) 2014-12-17 2020-05-14 Pimco 2664 Limited N-(4-hydroxy-4-methyl-cyclohexyl)-4-phenyl-benzenesulfonamide and N-(4-hydroxy-4-methyl-cyclohexyl)-4-(2-pyridyl)-benzenesulfonamide compounds and their therapeutic use
JP6680888B2 (ja) 2016-01-14 2020-04-15 リサーチ・コオペレイション・ファウンデイション・オブ・ユンナム・ユニヴァーシティＲｅｓｅａｒｃｈ Ｃｏｏｐｅｒａｔｉｏｎ Ｆｏｕｎｄａｔｉｏｎ Ｏｆ Ｙｅｕｎｇｎａｍ Ｕｎｉｖｅｒｓｉｔｙ ピリジノール誘導体またはその薬剤学的に許容可能な塩およびこれを有効成分として含有する薬学組成物
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
MX2021005801A (es) 2018-11-20 2021-08-05 Sparrow Pharmaceuticals Inc Metodos para administrar corticosteroides.
IL316907A (en) 2022-05-16 2025-01-01 Sparrow Pharmaceuticals Inc METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOD EXCESS

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2312728A1 (de) 1972-03-16 1973-09-20 Ciba Geigy Ag Verfahren zur herstellung von im kern sulfonierten verbindungen
EP0682016A1 (en) 1994-05-13 1995-11-15 Zeneca Limited Pyridine derivatives
US20030166689A1 (en) 2000-05-22 2003-09-04 Guido Kurz Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003099773A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
WO2005060963A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
US20050282802A1 (en) 2004-04-13 2005-12-22 Elena Kostik Disalt inhibitors of IL-12 production
US20060009455A1 (en) 2004-06-15 2006-01-12 Corte James R Six-membered heterocycles useful as serine protease inhibitors
WO2006014012A2 (en) 2004-08-06 2006-02-09 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds
WO2006024779A1 (fr) 2004-08-03 2006-03-09 Sanofi-Aventis Derives de sulfonamides, leur preparation et leur application en therapeutique
US20060063779A1 (en) 2004-09-02 2006-03-23 Gunzner Janet L Pyridyl inhibitors of hedgehog signalling
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US20060074237A1 (en) 2004-10-04 2006-04-06 Kurt Amrein Pyridines

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2312728A1 (de) 1972-03-16 1973-09-20 Ciba Geigy Ag Verfahren zur herstellung von im kern sulfonierten verbindungen
EP0682016A1 (en) 1994-05-13 1995-11-15 Zeneca Limited Pyridine derivatives
US20030166689A1 (en) 2000-05-22 2003-09-04 Guido Kurz Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
WO2003099773A1 (en) 2002-05-24 2003-12-04 Millennium Pharmaceuticals, Inc. Ccr9 inhibitors and methods of use thereof
WO2005060963A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
US20050148631A1 (en) 2003-12-19 2005-07-07 Agouron Pharmaceuticals, Inc. Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US20050282802A1 (en) 2004-04-13 2005-12-22 Elena Kostik Disalt inhibitors of IL-12 production
US20060009455A1 (en) 2004-06-15 2006-01-12 Corte James R Six-membered heterocycles useful as serine protease inhibitors
WO2006024779A1 (fr) 2004-08-03 2006-03-09 Sanofi-Aventis Derives de sulfonamides, leur preparation et leur application en therapeutique
WO2006014012A2 (en) 2004-08-06 2006-02-09 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds
US20060063779A1 (en) 2004-09-02 2006-03-23 Gunzner Janet L Pyridyl inhibitors of hedgehog signalling
WO2006034440A2 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
US20060074237A1 (en) 2004-10-04 2006-04-06 Kurt Amrein Pyridines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PCT International Search Report, PCT/IB2006/001581.

Also Published As

Publication number Publication date
BRPI0611853A2 (pt) 2010-10-05
EP1893609B1 (en) 2009-11-18
ES2334518T3 (es) 2010-03-11
NO20080164L (no) 2008-03-14
MA29550B1 (fr) 2008-06-02
JP2008543825A (ja) 2008-12-04
NL1031976C2 (nl) 2007-04-17
AU2006257646A1 (en) 2006-12-21
UY29606A1 (es) 2007-01-31
AR055060A1 (es) 2007-08-01
TW200736223A (en) 2007-10-01
PE20070136A1 (es) 2007-03-08
TNSN07476A1 (fr) 2009-03-17
ATE449094T1 (de) 2009-12-15
JP4250675B2 (ja) 2009-04-08
CA2610903A1 (en) 2006-12-21
EP1893609A1 (en) 2008-03-05
EA200702498A1 (ru) 2008-06-30
IL187695A0 (en) 2008-08-07
WO2006134467A1 (en) 2006-12-21
TWI304062B (en) 2008-12-11
GT200600258A (es) 2007-02-26
NL1031976A1 (nl) 2006-12-19
KR20080016649A (ko) 2008-02-21
MX2007016319A (es) 2008-03-10
US20070072914A1 (en) 2007-03-29
DE602006010546D1 (de) 2009-12-31

Similar Documents

Publication Publication Date Title
US7462634B2 (en) N-(pyridin-2-yl)-sulfonamide derivatives
US10626125B2 (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives as MAGL inhibitors
JP4719469B2 (ja) 置換アミド類
US20070027118A1 (en) Novel compounds of amino sulfonyl derivatives
US20050148631A1 (en) Amino heterocyclyl inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
US9440954B2 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
US20060111416A1 (en) Octahydropyrrolo[3,4-C]pyrrole derivatives
US12428375B2 (en) Compounds and compositions for treating conditions associated with LPA receptor activity
US20210309669A1 (en) Heterocyclic Spiro Compounds As MAGL Inhibitors
US20220185785A1 (en) Inhibitors of cd40-cd154 binding
PL193438B1 (pl) Pochodna 5-podstawionego-1,2,4-tiadiazolilu, jej zastosowanie i sposób wytwarzania, kompozycja farmaceutyczna, karbotioaminowa pochodna piperazyny i sposób jej wytwarzania
WO2007045989A1 (en) Pyridyl derivatives useful as h3 ligands
CN101198605A (zh) N-(吡啶-2-基)-磺酰胺衍生物
US20060040977A1 (en) 5-HT7 receptor ligands
JP2001525398A (ja) 選択的β３アドレナリン作動性アゴニスト
US7863276B2 (en) Salts of modulators of PPAR and methods of treating metabolic disorders
HK1117509A (en) N-(pyridin-2-yl)-sulfonamide derivatives
WO2005100322A1 (en) Sulphur-linked imidazole compounds for the treament of hiv
TW510901B (en) Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives
JP2757353B2 (ja) インダン誘導体、その製法及びその合成中間体
US20240360119A1 (en) Small molecule urea derivatives as sting antagonists
CA2592909A1 (en) Imidazole derivatives as enzyme reverse transcriptase modulators
JPWO1998013348A1 (ja) 置換ビニルピリジン誘導体及びこれを含有する医薬

Legal Events

Date Code Title Description
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20121209